Regulation - Pricing, Markets & Marketing


Popular Filters

NICE consults on draft guidance backing Invokana, as drug debuts in the UK


UK drugs watchdog the National Institute for Health and Care Excellence is currently appraising Invokana…

DiabetesInvokanaJanssen-CilagJohnson & JohnsonMarkets & MarketingNorthern EuropePharmaceuticalPricingRegulationUK

Report: India’s strong commercial opportunities hampered by bureaucracy and poor policy planning

Report: India’s strong commercial opportunities hampered by bureaucracy and poor policy planning


Due to its large population and substantial unmet medical needs, India represents a market with strong…

Asia-PacificIndiaMarkets & MarketingPharmaceuticalPricingRegulation

Generics market in Southeast Asia set for growth


With its fast-growing, young population and uninsured majority in Southeast Asia, countries in the region…

Asia-PacificGenericsMarkets & MarketingPricingRegulation

Eisai temporarily suspend Fycompa in Germany, following negative G-BA decision


Japanese drug major Eisai (TYO: 4523) said today (June 25) that, "with regret," it will suspend temporarily…

EisaiEuropeFycompaMarkets & MarketingNeurologicalPharmaceuticalPricingRegulation

BRICs not delivering promises of high growth in health care markets, says F&S


Health care organizations expanding into emerging markets such as the BRICs (Brazil, Russia, India and…

HealthcareMarkets & MarketingPharmaceuticalPricingRegulation

Launching new drugs in the Outcome Era; report


The pharmaceutical industry is facing the Outcome Era. Launching a novel drug today obliges companies…

GlobalMarkets & MarketingPharmaceuticalPricingRegulation

"India Pharma Inc" gearing up for the next level of growth


Indian pharmaceutical companies will have to rethink business strategy in the light of several interventions…

Asia-PacificGenericsHealthcareMarkets & MarketingPharmaceuticalPricingProductionRegulation

A blip or stark reality? Pharma companies re-evaluate emerging markets


Pharmaceutical companies, which have previously been allaying the growing fears and concerns of their…

FinancialGlobalMarkets & MarketingPharmaceuticalPricingRegulation

Australia's health care regulations struggle to keep up with population aging


The growing elderly population and its associated disease burden add to the economic challenges faced…

Asia-PacificHealthcareMarkets & MarketingPharmaceuticalPricingRegulation

Biopharmaceuticals "no longer a growth market" in Germany


After years of consistent growth, the German biopharmaceuticals market came to a juddering halt last…

BiotechnologyEuropeMarkets & MarketingPharmaceuticalPoliticsPricingRegulation

Legislative changes to hamper near-term innovative drugs market in Central Europe


Due to legislative changes implemented during 2011 in most of the Central European (CE) countries, the…

EuropeGenericsMarkets & MarketingPharmaceuticalPricingRegulation

EU Commission proposes faster access to medicines for patients


With the intention of getting new medicines to the market faster, the European Commission yesterday proposed…

EuropeGenericsMarkets & MarketingPharmaceuticalPricingRegulation

GSK boss accuses UK government of blocking new drugs to save money


The chief executive of the UK’s largest pharmaceutical company, GlaxoSmithKline (LSE: GSK) has accused…

EuropeGlaxoSmithKlineMarkets & MarketingPharmaceuticalPricingRegulation

Reinventing biopharma: Strategies for an evolving marketplace


The biopharmaceutical industry today is facing a multifaceted “value challenge”. It is no longer…

BiotechnologyGlobalMarkets & MarketingPharmaceuticalPricingRegulation

German pharma hails successful 2011; views AMNOG


The German pharmaceutical industry can be proud of its progress last year, said Birgit Fischer, director…

EuropeMarkets & MarketingPharmaceuticalPricingRegulation

Australia’s GMiA completes Code review; comments on PBS cuts and vital role of pharma manufacturing


Martin Cross, chairman of Australia’s Generic Medicines Industry Association (GMiA) has warned that…

Asia-PacificGenericsMarkets & MarketingPharmaceuticalPricingRegulation

Back to top